Asha Pillai is an Oncology physician affiliated with Regeneron. OpenAlex indexes 91 publications with 1,342 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-243-8213Provider last certified this registry record 12 Aug 2020.
Clinical trials
- Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
Sponsor: St. Jude Children's Research Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 2015–2021 per NIH RePORTER. The latest:
- NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES
University of Miami School of Medicine
FY2021$441,168R01HL133462 - NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES
University of Miami School of Medicine
FY2020$441,168R01HL133462 - NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES
University of Miami School of Medicine
FY2019$383,750R01HL133462
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gender Inequity in Institutional Leadership Roles in US Academic Medical Centers
JAMA Network Open
2025 - Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy
Cancer Treatment and Research Communications
2025 - Anaphylaxis to Cyclophosphamide Metabolites during Lymphodepletion for CAR-T Therapy
Biology of Blood and Marrow Transplantation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Kimberly
Regeneron
Robert Vitti, MD
Regeneron
Thomas Uldrick, MD
Regeneron
Andrew Fontenot, MD
Regeneron
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”